Blueprint Medicines Corporation (Nasdaq: BPMC) has announced that as of March 1, 2024, the Compensation Committee of its Board of Directors has approved the granting of non-qualified stock options to…
CRISPR Therapeutics, a leading biopharmaceutical firm dedicated to pioneering gene-based treatments for severe illnesses, has unveiled its proposal to appoint Christian Rommel, Ph.D., to its Board of Directors during the…
UCB, a global biopharmaceutical company, has unveiled the findings of 48-week post-hoc analyses derived from pooled Phase 3 data originating from the BE HEARD I and BE HEARD II trials.…
Amgen Unveils New Research on Otezla® (Apremilast) at AAD 2024 Amgen, a leader in biotechnology, has disclosed fresh findings from the Phase 3 SPROUT trial, investigating Otezla® (apremilast) in children…
Novo Nordisk has announced today that the US Food and Drug Administration (FDA) has granted approval for an expanded label for Wegovy®. This approval, based on a supplemental New Drug…
Eli Lilly and Company (NYSE: LLY) has disclosed findings from a pioneering investigation into lebrikizumab, tailored specifically for individuals with skin of color grappling with moderate-to-severe atopic dermatitis, commonly known…
Eli Lilly and Company (NYSE: LLY) has announced that the U.S. Food and Drug Administration (FDA) plans to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory…
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading biopharmaceutical firm specializing in the discovery, acquisition, development, and distribution of innovative therapies for rare and orphan diseases, has revealed its participation in…
Oragenics, Inc. (NYSE American: OGEN), a company dedicated to developing innovative intranasal pharmaceuticals for neurological disorders, has revealed its readiness to embark on the final stages of GMP manufacturing and…
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on seralutinib for pulmonary arterial hypertension (PAH) treatment, reported its financials for Q4 and full-year 2023 and updated on business…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNAi therapeutics, has announced positive results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT)…
Argonaut Manufacturing Services Secures $45M Funding for Expanded Pharma Fill / Finish Facility Argonaut Manufacturing Services, a prominent contract development and manufacturing organization in the biopharma and life sciences sectors,…